Familial hypercholesterolemia is a genetic disorder characterized by high cholesterol levels, leading to an increased risk of early cardiovascular diseases. It accounts for approximately 450,000 children born annually. However, only 2.1% of adults are diagnosed before age 18. There is a significant clinical need for better therapies, as current treatments, such as statins and LDL apheresis, are not always effective. The growing focus on gene therapy, novel lipid-lowering drugs, and advanced therapeutics is likely to support pipeline growth, offering promising familial hypercholesterolemia treatment options in the coming years.
Major companies involved in the familial hypercholesterolemia pipeline drugs market include Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, and others.
Leading drugs currently in the pipeline include ARO-ANG3 and VERVE-101, among others.
The increasing awareness, advancements in genetic research, and rising demand for targeted therapies are positively impacting the familial hypercholesterolemia drug pipeline.
The Familial Hypercholesterolemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into familial hypercholesterolemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for familial hypercholesterolemia. The familial hypercholesterolemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The familial hypercholesterolemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with familial hypercholesterolemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to familial hypercholesterolemia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Familial hypercholesterolemia is a genetic disorder characterized by abnormally high levels of low-density lipoprotein cholesterol (LDL-C) in the blood. It occurs due to mutations in the LDL receptor gene, impairing the liver's ability to remove LDL-C. This leads to early plaque buildup in arteries, increasing the risk of heart disease.
Familial hypercholesterolemia treatment typically involves statins to lower LDL-C levels, PCSK9 inhibitors to further reduce cholesterol, and ezetimibe to block cholesterol absorption in the intestines. In severe cases, LDL apheresis, a procedure to remove excess cholesterol from the blood, may be necessary. Liver transplantation is an option for those with severe cases of unresponsiveness to medications.
Familial hypercholesterolemia affects approximately 450,000 children born globally each year, yet only 2.1% of adults are diagnosed before the age of 18. Around 1.3 million individuals in the United States have familial hypercholesterolemia, with only 10% being aware of their condition. The condition is estimated to impact about 270,000 people in the United Kingdom, 1 in 300 individuals in Japan, and 0.1% of the population in India.
This section of the report covers the analysis of familial hypercholesterolemia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total familial hypercholesterolemia clinical trials.
The drug molecule categories covered under the familial hypercholesterolemia pipeline analysis include monoclonal antibodies, gene therapies, small molecules, RNA-based therapies, and enzyme inhibitors. The familial hypercholesterolemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for familial hypercholesterolemia.
The EMR report for the familial hypercholesterolemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed familial hypercholesterolemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in familial hypercholesterolemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for familial hypercholesterolemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of familial hypercholesterolemia drug candidates.
Enlicitide Decanoate (MK-0616), an oral PCSK9 inhibitor, is being evaluated in the Phase III CORALreef study. The study, sponsored by Merck Sharp & Dohme LLC, aims to assess its efficacy, safety, and tolerability in adults with heterozygous familial hypercholesterolemia.
ARO-ANG3 is an investigational RNAi therapeutic targeting ANGPTL3, a protein regulating lipid metabolism, to potentially improve lipid clearance and lower cholesterol levels. The Phase II study of ARO-ANG3, sponsored by Arrowhead Pharmaceuticals, aims to evaluate the safety and efficacy of ARO-ANG3 in participants with homozygous familial hypercholesterolemia (HoFH). The study will involve up to 36 weeks of treatment with an optional 24-month extension.
VERVE-101, developed by Verve Therapeutics, is undergoing a Phase I clinical trial to assess its safety in patients with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD). This single-dose, liver-base-editing drug targets the PCSK9 gene to reduce LDL-C levels, aiming to improve cardiovascular health in patients with uncontrolled hypercholesterolemia.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Familial Hypercholesterolemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for familial hypercholesterolemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into familial hypercholesterolemia collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share